Sustained drug-free remission in rheumatoid arthritis associated with diffuse large B-cell lymphoma following tandem CD20-CD19-directed non-cryopreserved CAR-T cell therapy using zamtocabtagene autoleucel

Szabo, David ✉; Balogh, Alexandra; Gopcsa, Laszlo [Gopcsa, László (Belgyógyászat, he...), author]; Giba-Kiss, Laura; Lakatos, Gergely; Paksi, Melinda; Reti, Marienn [Réti, Marienn Györgyi (Hematológia, tran...), author]; Takacs, Peter; Heteren, Pearl van; Zadoyan, Gregor; Holtkamp, Silke; Overstijns, Toon; Miltenyi, Stefan; Remenyi, Peter [Reményi, Péter (Belgyógyászat, he...), author]; Nagy, György [Nagy, György (Immunológia), author] Department of Genetics, Cell- and Immunology (SU / FM / I); Department of Cardiology – Heart and Vascular C... (SU / FM / C); Department of Rheumatology and Clinical Immunology (SU / FM / C / DIMO)

English Article (Journal Article) Scientific
Published: RMD OPEN 2056-5933 2056-5933 10 (4) Paper: e004727 , 6 p. 2024
  • SJR Scopus - Rheumatology: D1
Identifiers
Subjects:
  • Biological basis of immunity related disorders (e.g. autoimmunity)
We report the case of long-term persisting rheumatoid arthritis (RA), treated with CD20-CD19 CAR-T when it became associated with diffuse large B cell lymphoma (DLBCL), resulting in a sustained drug-free remission of the preceding RA, as well as of the subsequent DLBCL that formed the indication of the CAR-T therapy using zamtocabtagene autoleucel, with a 1-year follow-up. According to our best knowledge, this is the first published clinical case report of long-term persisting RA treated with CAR-T cell therapy.
Citation styles: IEEEACMAPAChicagoHarvardCSLCopyPrint
2025-04-16 17:52